Recognizing the symptoms of optic nerve damage at an early stage, and contacting an eye specialist will help prevent total blindness. Some may experience loss of vision within a day or a week. The damage often results in permanent loss of vision. The severity of the damage, in case of opticl neuritis, may be increased by heat or exercise. Optic nerve, also known as cranial nerve, is a part of the central nervous system. Read More HereMostly, patients diagnosed with optical nerve damage experience permanent vision loss. webInflammation of the spinal cord and optic nerve, known as neuromyelitis optica. is an autoimmune disorder, which can affect the function of the nerves. Studies regarding ‘neural stem cell therapy’ show that certain therapy can prove to be beneficial for the restoration of sight after optic nerve injury, in the future. Therefore, optic nerve damage from glaucoma and other diseases or trauma is irreversible. Hence, for any type of eye problem, you should immediately contact an ophthalmologist.
Simultaneously, the Company initiated its reimbursement filings, commercial and market development activities. Khalid Ishaque, added: In parallel, the company continues to progress on its second system, PRIMA, a wireless sub-retinal implant, with a less invasive design particularly suitable for AMD. We completed the pre-clinical studies enabling submission for a feasibility study for AMD. Regulatory approval for the first human implantation is expected by end 2016. Revenues of the first nine months Closing cash and cash equivalents 17,338.1 28,082.2 During the first nine months of 2016, Other revenues amounted to 1.9 million, down 27% compared to the prior year. As no R&D expense is activated, the research tax credit (RTC) is fully accounted for as other revenues. For the first nine months of 2016, the Company recorded a net income related to RTC of 1.80 million compared to 1.96 million one year earlier. This RTC level is down slightly due to the reduction of research expenditures on IRISII, which received CE market approval in July. Additionally, in 2016, the Company received a grant of 122,159 in relation to the GRAPHENE project. The Company also received in 2015, a grant of 471,593 provided by Bpifrance under the SIGHT AGAIN project. The net use of cash flow from operating activities at 30 September 2016 amounted to 8.9 million compared to 12.1 million over the same period in 2015. Since its IPO, the company has been developing in parallel two Bionic Vision Systems. IRISII is currently in clinical trials and PRIMA recently completed the preclinical study phase.
For the original version including any supplementary images or video, visit http://www.businesswire.com/news/home/20161026006631/en/Pixium-Vision-Results-9-Months-2016